The logo of Swiss drugmaker Novartis is pictured at the company's French headquarters in Rueil-Malmaison (Reuters) -Voyager Therapeutics said on Tuesday Swiss-based drugmaker Novartis would pay $100 ...
In Novartis’ perennial hunt for innovative therapies to bring under its wing, improving on gene therapy has always been kept top of mind. And the Swiss pharma continues to do just that thanks to a new ...
Novartis inked a strategic collaboration and capsid license agreement with Voyager Therapeutics on Tuesday that could total $1.3 billion. The Swiss pharma giant is gaining target-exclusive access to ...
Two months ago, Novartis Gene Therapies chief Dave Lennon left the company to lead a biotech startup that is operating in stealth mode. It was with similar stealth that the unit Lennon formerly headed ...
Developed by Novartis, ITVISMA is a one-time therapy for patients aged 2 and older with a confirmed SMN1 gene mutation. The ...
More than five years after an initial FDA approval, Novartis is touting positive trial results for its radiotherapy Lutathera as a first-line therapy against the rare cancer that killed Apple ...
Basel, November 10, 2025 – Novartis, a leading global innovative medicines company, today announced the opening of a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad ...
Novartis has acknowledged that two patients have died of acute liver failure following treatment with its Zolgensma ® (onasemnogene abeparvovec-xioi), a one-time gene therapy indicated for some forms ...
Basel, June 11, 2021 — Novartis today announced new Phase II data for iptacopan (LNP023), an investigational oral treatment for paroxysmal nocturnal hemoglobinuria (PNH), presented at the 26th Annual ...
The FDA decision announced Wednesday covers adults whose cancer is positive for prostate-specific membrane antigen (PSMA), a protein abundant on the surface of prostate cancer cells. The Novartis ...
According to financial terms announced Wednesday, Novartis is paying Gyroscope $800 million up front. Depending on the progress of Gyroscope’s therapies, that company’s shareholders could receive up ...
(Reuters) -Voyager Therapeutics said on Tuesday Swiss-based drugmaker Novartis would pay $100 million upfront as part of a licensing deal to develop gene therapy candidates for genetic disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback